Omega-3 Scientific References and Clinical Study Library

Omega-3 Scientific References and Clinical Study Library: Evidence Guide
Omega-3 scientific references are the fastest way to separate solid evidence from marketing claims. Fish oil, krill oil and algal oil are heavily promoted, yet the research behind them ranges from large, carefully run trials to small laboratory experiments. This library collects the key sources in one place, sorted by study type, so you can see what each one can and cannot tell you. Use it to check a claim, to prepare questions for your doctor, or to find the original paper behind a headline. Every entry below links to its DOI so you can read the source yourself.
Educational information only. It does not replace advice from a qualified healthcare professional. Details were compiled from the cited sources; always confirm numbers against the original paper.
1. How This Omega-3 Research Library Is Organized
The library follows the usual evidence pyramid, from strongest to weakest for answering "does this work in people?" questions.
- Systematic reviews and meta-analyses pool many studies and sit at the top.
- Randomized controlled trials (RCTs) are the best single-study design for testing cause and effect.
- Observational studies show associations in real populations but cannot prove cause.
- Pharmacokinetic studies show how the body absorbs and uses different products.
- Safety and toxicology studies describe tolerable doses and quality concerns.
- Mechanistic and preclinical studies explain how omega-3 fats might work, in cells, tissues and animals, but do not by themselves prove a result in people.
Omega-3 fatty acids here mean EPA and DHA from marine sources and ALA from plants. Unless stated, the trials below used marine EPA and DHA. Doses are given per day.
Every link uses the format https://doi.org/ followed by the DOI. To find the PubMed record, paste the DOI into the PubMed search box (https://pubmed.ncbi.nlm.nih.gov/).
2. Systematic Reviews on Omega-3 Clinical Studies
Systematic reviews gather every eligible study on a question using a fixed method, which reduces cherry-picking.
- Abdelhamid AS et al., 2018. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. Reviewed 79 randomized trials with over 100,000 participants. Found that increasing omega-3 intake probably makes little or no difference to most cardiovascular outcomes. DOI: https://doi.org/10.1002/14651858.CD003177.pub3
- Middleton P et al., 2018. Omega-3 fatty acid addition during pregnancy. Cochrane Database of Systematic Reviews. Pooled trials in pregnant women and found a lower risk of preterm birth with omega-3 supplementation. DOI: https://doi.org/10.1002/14651858.CD003402.pub3
- Calder PC, 2010. Omega-3 fatty acids and inflammatory processes. Nutrients. A narrative review of how EPA and DHA influence inflammation. DOI: https://doi.org/10.3390/nu2030355
How to read them: Cochrane reviews are rigorous, but they are only as good as the trials they include, and many older trials used small doses or short follow-up.
3. Meta-Analyses
Meta-analyses combine the numerical results of several trials into one estimate.
- Hu Y, Hu FB, Manson JE, 2019. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled trials. Journal of the American Heart Association. About 127,000 participants. Found modest reductions in some cardiovascular outcomes, such as heart attack, with no clear effect on overall mortality. DOI: https://doi.org/10.1161/JAHA.119.013543
- Gencer B et al., 2021. Effect of long-term marine omega-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes. Circulation. Seven RCTs, roughly 81,000 participants. Reported a higher risk of atrial fibrillation with supplementation, with a larger increase at doses above 1 g per day. DOI: https://doi.org/10.1161/CIRCULATIONAHA.121.055654
How to read them: Meta-analyses can mix very different doses and products, so a pooled number may hide important differences between EPA-only and EPA plus DHA preparations.
4. Omega-3 Clinical Studies: Randomized Controlled Trials
These are the landmark trials that shaped current guidance.
- GISSI-Prevenzione Investigators, 1999. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction. The Lancet. About 11,000 Italian heart attack survivors took roughly 1 g per day. Showed a reduction in a combined cardiovascular endpoint. DOI: https://doi.org/10.1016/S0140-6736(99)07072-5
- Yokoyama M et al., 2007 (JELIS). Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients. The Lancet. Open-label trial in about 18,600 Japanese adults on statins, 1.8 g per day of EPA. Reported fewer major coronary events. DOI: https://doi.org/10.1016/S0140-6736(07)60527-3
- ASCEND Study Collaborative Group, 2018. Effects of n-3 fatty acid supplements in diabetes mellitus. New England Journal of Medicine. About 15,500 adults with diabetes took 1 g per day for a median of over seven years. No significant reduction in serious vascular events. DOI: https://doi.org/10.1056/NEJMoa1804989
- Manson JE et al., 2019 (VITAL). Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine. About 25,900 healthy adults took 1 g per day for a median of about five years. No significant reduction in the main cardiovascular or cancer endpoints. DOI: https://doi.org/10.1056/NEJMoa1811403
- Bhatt DL et al., 2019 (REDUCE-IT). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine. About 8,200 high-risk adults took 4 g per day of purified EPA. Reported a lower rate of cardiovascular events, along with more atrial fibrillation. DOI: https://doi.org/10.1056/NEJMoa1812792
- Nicholls SJ et al., 2020 (STRENGTH). Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk. JAMA. About 13,000 adults took 4 g per day of EPA plus DHA. Stopped early for lack of benefit. DOI: https://doi.org/10.1001/jama.2020.22258
How to read them: Results differ between trials because of dose, product (purified EPA versus EPA plus DHA), population risk and the placebo used. No single trial answers every question.
5. Observational Human Studies
Observational studies follow people as they live, without assigning a treatment. They generate ideas, but cannot prove cause and effect.
- Dyerberg J, Bang HO, Hjorne N, 1978. Fatty acid composition of the plasma lipids in Greenland Eskimos. The Lancet. An early study that sparked interest in marine fats and heart health. DOI: https://doi.org/10.1016/S0140-6736(78)91505-2
- Hu FB et al., 2002. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. Nurses' Health Study data on about 84,700 women followed for 16 years, linking higher fish intake to lower coronary disease risk. DOI: https://doi.org/10.1001/jama.287.14.1815
- Brasky TM et al., 2013. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. Journal of the National Cancer Institute. Found an association between higher blood omega-3 levels and high-grade prostate cancer. This remains debated and inconsistent across studies. DOI: https://doi.org/10.1093/jnci/djt174
How to read them: People who eat more fish may differ in many ways, such as diet, exercise and income, so confounding is a real problem.
6. Pharmacokinetic Studies: How the Body Handles Omega-3
Pharmacokinetic studies measure absorption, blood levels and how long compounds stay in the body.
- Dyerberg J et al., 2010. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins, Leukotrienes and Essential Fatty Acids. Compared natural triglyceride, ethyl ester and free fatty acid forms. Found that ethyl esters were absorbed less well than other forms. DOI: https://doi.org/10.1016/j.plefa.2010.06.007
- Schuchardt JP, Hahn A, 2013. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins, Leukotrienes and Essential Fatty Acids. Reviewed how absorption varies with chemical form, with food (especially fat in a meal) and between fish oil and krill oil. DOI: https://doi.org/10.1016/j.plefa.2013.03.010
How to read them: Absorption data are useful for choosing how to take a product, such as with a meal, but a higher blood level does not automatically mean a better health outcome.
7. Safety and Toxicology Studies
These sources define tolerable intakes and quality concerns.
- EFSA Panel on Dietetic Products, Nutrition and Allergies, 2012. Scientific opinion on the tolerable upper intake level of EPA, DHA and DPA. EFSA Journal. Concluded that long-term supplemental intakes of EPA and DHA combined up to 5 g per day did not raise safety concerns for adults. DOI: https://doi.org/10.2903/j.efsa.2012.2815
- Albert BB et al., 2013. Oxidation of marine omega-3 supplements and human health. BioMed Research International. Reviewed oxidation in fish oil products and its possible health effects. DOI: https://doi.org/10.1155/2013/464921
- U.S. Food and Drug Administration. GRAS affirmation for menhaden oil, 21 CFR 184.1472, supporting intakes of up to 3 g per day of EPA plus DHA, of which no more than 2 g should come from supplements. Official source: https://www.ecfr.gov
How to read them: Regulatory limits are not targets. Our companion page on omega-3 safety explains side effects, contraindications and when to stop.
8. Mechanistic Studies
Mechanistic studies explore how omega-3 fats might act on cells and pathways.
- Calder PC, 2010. (see Section 2) Describes how EPA and DHA compete with omega-6 fats and affect inflammatory signalling. DOI: https://doi.org/10.3390/nu2030355
- Serhan CN, 2014. Pro-resolving lipid mediators are leads for resolution physiology. Nature. Describes how DHA and EPA are converted into molecules that help switch off inflammation. DOI: https://doi.org/10.1038/nature13479
- Mozaffarian D, Wu JHY, 2011. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. Journal of the American College of Cardiology. Links effects on triglycerides, blood pressure and heart rhythm to clinical outcomes. DOI: https://doi.org/10.1016/j.jacc.2011.06.063
How to read them: A plausible mechanism is a reason to run a trial, not a guarantee of benefit. The large trials above show why this matters.
9. Preclinical Studies
Preclinical work uses cells and animals. It is valuable for hypotheses but is the weakest evidence for human outcomes.
- Bazinet RP, Layé S, 2014. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nature Reviews Neuroscience. Reviews laboratory and animal evidence on how DHA is used in the brain. DOI: https://doi.org/10.1038/nrn3820
Results in animals often use doses, delivery routes or species differences that do not translate to people. When a headline cites a mouse or cell study, look for human trials before drawing conclusions.
10. Omega-3 Study Table: Year, Design, Population and Dose
This table summarizes the main studies at a glance. Numbers are rounded.
|
Study |
Year |
Design |
Population |
Dose per day |
|---|---|---|---|---|
|
GISSI-Prevenzione |
1999 |
RCT |
About 11,300 post-heart-attack patients, Italy |
About 1 g EPA plus DHA |
|
JELIS |
2007 |
Open-label RCT |
About 18,600 adults with high cholesterol on statins, Japan |
1.8 g EPA |
|
ASCEND |
2018 |
RCT |
About 15,500 adults with diabetes, UK |
1 g EPA plus DHA |
|
VITAL |
2019 |
RCT |
About 25,900 adults without prior heart disease or cancer, USA |
1 g EPA plus DHA |
|
REDUCE-IT |
2019 |
RCT |
About 8,200 high-risk adults with raised triglycerides |
4 g icosapent ethyl (EPA) |
|
STRENGTH |
2020 |
RCT |
About 13,000 high-risk adults with raised triglycerides |
4 g EPA plus DHA |
|
Cochrane CVD review |
2018 |
Systematic review |
79 RCTs, over 100,000 participants |
Varied |
|
Cochrane pregnancy review |
2018 |
Systematic review |
About 70 RCTs in pregnant women |
Varied |
|
Hu meta-analysis |
2019 |
Meta-analysis |
13 RCTs, about 127,000 participants |
Varied |
|
Gencer meta-analysis (AF) |
2021 |
Meta-analysis |
7 RCTs, about 81,000 participants |
Up to about 4 g |
|
Nurses' Health Study (Hu) |
2002 |
Cohort |
About 84,700 women |
Dietary fish intake |
|
SELECT analysis (Brasky) |
2013 |
Case-cohort |
Men in the SELECT trial |
Blood levels, not a dose |
11. DOI, PubMed and Official Links
Use these steps to check any claim yourself.
- Open the DOI link in the entry above. It leads to the publisher's page, where the abstract is usually free.
- Search PubMed at https://pubmed.ncbi.nlm.nih.gov/ by pasting the DOI or the paper title. PubMed also shows related articles and corrections.
-
Check official summaries from public-health bodies:
- NIH Office of Dietary Supplements, Omega-3 Fatty Acids fact sheet for health professionals: https://ods.od.nih.gov/factsheets/Omega3FattyAcids-HealthProfessional/
- NCCIH, Omega-3 Supplements: What You Need To Know: https://www.nccih.nih.gov/health/omega3-supplements-what-you-need-to-know
- European Food Safety Authority, scientific opinions: https://www.efsa.europa.eu
- Look for retractions or updates before relying on any single paper.
A quick checklist for judging a study: How many people took part? How long did it last? What dose and product were used? Who funded it? Was it compared with a placebo? Do other studies agree?
For general information only. Talk to your doctor before starting any supplement.


